Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women. After week 10, participants continued to receive prazosin or placebo in a double-blind fashion for an additional 16 weeks. The three primary outcome measures were the change in score from baseline to 10 weeks on the Clinician-Administered PTSD Scale (CAPS) item B2 ("recurrent distressing dreams"; scores range from 0 to 8, with higher scores indicating more frequent and more distressing dreams); the change in score from baseline to 10 weeks on the Pittsburgh Sleep Quality Index (PSQI; scores range from 0 to 21, with higher scores indicating worse sleep quality); and the Clinical Global Impression of Change (CGIC) score at 10 weeks (scores range from 1 to 7, with lower scores indicating greater improvement and a score of 4 indicating no change). RESULTS: A total of 304 participants underwent randomization; 152 were assigned to prazosin, and 152 to placebo. At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96). There were no significant differences in these measures at 26 weeks (a secondary outcome) or in other secondary outcomes. At 10 weeks, the mean difference between the prazosin group and the placebo group in the change from baseline in supine systolic blood pressure was a decrease of 6.7 mm Hg. The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo. CONCLUSIONS: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Funded by the Department of Veterans Affairs Cooperative Studies Program; PACT ClinicalTrials.gov number, NCT00532493 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a position paper by the American Academy of Sleep Medicine (AASM) has highlighted a contradictory study [33] and downgraded its recommendation for prazosin, but still considers it to be the first-line pharmacological choice [34].”
From Nightmare Disorder and Isolated Sleep Paralysis (2021) · cites this paper as [33]
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J.-D., Ding, Y.-S., Henry, S., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
RetractedThe PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Bush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Self-citationRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
Self-citation
Research works printed but not linked: 3
- Guy W. CDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
- Frisch MB. Manual and treatment guide for the Quality of Life Inventory (QOLI). Minneapolis: Pearson Assessments 1994.
- The Management of Posttraumatic Stress Disorder Working Group. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.
Cited by
Items 201–300 of 355
Holzinger, B., & Stefani, A. (2020) · Handbuch Schlafmedizin · doi:10.1016/b978-3-437-21321-2.00040-5 · Cited by 3
Provini, F., Högl, B., Iranzo, Á., Kushida, C. A., Lee, J., Shukla, G., Stefani, A., Wing, Y. K., & Malkani, R. G. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.01.001 · Cited by 3
Sidik, A. I., Dontsov, V. V., Ruchkin, M. G., Kapieva, N. S., Alimagomaev, B. M., Epimakhova, O. S., Toktarova, N. M., BADOIAN, A. A., Falchinsky, A. N., Kirkevich, N. D., et al. (2025) · Cureus · doi:10.7759/cureus.100349 · Cited by 8
Song, J. (2026) · iScience · doi:10.1016/j.isci.2026.115447 · Cited by 3
“Prazosin, a centrally acting alpha-1 adrenergic receptor antagonist, was historically relied upon based on the mechanism of blocking excessive sympathetic signaling during sleep 194 (Table 3).”
Psychofarmaca en de behandeling van slaapstoornissen
van Veen, M., Kamphuis, J., & der Lek, R. F. R. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_19 · Cited by 3
Rossouw, J., Suliman, S., Nöthling, J., Lombard, C. J., Bröcker, E., Hewett, M., Simmons, C., Shorter, G. W., Seedat, S., Milanak, M. E., et al. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2024.2350217 · Cited by 4
“…psychological and pharmacological therapies being among the first-line treatments for PTSD in adults (Hamblen et al., 2019), research has shown that sleep disturbances often remain following these interventions (Belleville & Dubé-Frenette, 2015; Raskind et al., 2018; Zhang et al., 2022).”
BackgroundMyers, U. S., Keller, S. M., Grubaugh, A. L., & Tuerk, P. W. (2019) · Military Behavioral Health · doi:10.1080/21635781.2018.1543064 · Cited by 4
“However, the findings in this study are in line with those from the recent cooperative studies trial (Raskind et al., 2018), which suggest that prescription of prazosin may be outpacing the research supporting its effectiveness, particularly when prescribed in combination with evidence-based…”
Prazosin for nightmares in serious illness
Santivasi, W. L., Taylor, E., Christensen, A. R., & Strand, J. J. (2021) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2020-002594 · Cited by 3
Ranjbar, N., Khedmatgozari, A., Sadeghigolafshanl, M., Farhadi, S., & Hojjati, H. (2021) · Military Caring Sciences · doi:10.52547/mcs.8.2.101 · Cited by 3
Yan, J.-Z., Liu, J.-L., Li, X., Zhang, Z., Liu, R.-B., Zhang, C., & Gong, Q.-Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.805354 · Cited by 5
“…or different combat locations (Davidson et al., 1990; Stein et al., 2002; Bartzokis et al., 2005; Neylan et al., 2006; Raskind et al., 2007; Davis et al., 2008; Naylor et al., 2015; Petrakis et al., 2016; Villarreal et al., 2016; Ramaswamy et al., 2017; Surís et al., 2017; Raskind et al., 2018).”
BackgroundInfluentialRanney, R. M., Maguen, S., Woods, A., Seal, K. H., Neylan, T. C., Bernardy, N. C., Wiechers, I. R., Ryder, A. L., & Cohen, B. E. (2022) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13726 · Cited by 4
“The –22,34–37 Regarding mirtazapine, one study demonstrated that this medication may be efficacious as an augmenting medication for PTSD 23 ; however, more studies are needed to confirm this finding.”
Mahr, F., Waschbusch, D. A., & Vgontzas, A. N. (2023) · Cureus · doi:10.7759/cureus.42433 · Cited by 5
“In their trial, prazosin failed to show an appreciable decrease in nightmares or improvement in sleep quality [18].”
BackgroundMethodPOST-TRAUMATIC STRESS DISORDER AS PRESSING ISSUES OF OUR TIME
Mohylnyk, A., Zhyvotovska, L. V., Tarasenko, K. V., Boiko, D. I., Sonnik, Y., & Arkhipovets, O. (2023) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.23.3.203 · Cited by 3
“Велике мультицентрове дослі-дження у ветеранів воєн із хронічним ПТСР не виявило переваг препарату порівняно з плацебо [59].”
The Overlap Between Sleep Disorders and Psychiatric Disorders
Rao, N. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-44447-1_17 · Cited by 4
Sleep in Posttraumatic Stress Disorder
Miller, K. E., Brownlow, J. A., Ross, R. J. M., & Gehrman, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-0123-1_22 · Cited by 3
Wright, S. L., Kessler, A. S., Sijbrandij, M., Karyotaki, E., Cuijpers, P. J., Bisson, J. I., Brady, K. T., Dowd, S. M., Dunlop, B. W., Pollack, M. H., et al. (2025) · European Journal of Psychotraumatology · doi:10.1080/20008066.2025.2504839 · Cited by 2
“All trials ranged from 5 to 12 weeks, excluding two which were 24 weeks (Davidson et al., 2006A) and 26 weeks (Raskind et al., 2018).”
Post-traumatic stress disorder in psychedelic research
Bostoen, T., Tap, S. C., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.004 · Cited by 2
Zhao, Y., Huang, Z.-D., Gu, H.-Y., Guo, G., Yuan, R., & Zhang, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602447 · Cited by 2
“, 2017), alpha blockers (Raskind et al., 2007; Germain et al., 2012; Petrakis et al., 2016; Rodgman et al., 2016; Raskind et al., 2018), anticonvulsants (Hamner et al.”
BackgroundPharmakologische Behandlung der Posttraumatischen Belastungsstörung
Roepke, S., Schellong, J., Bergemann, N., Frommberger, U., & Schmidt, U. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01684-8 · Cited by 3
Willing, M. M. P., Tate, L. L., Riggs, D. S., DeGraba, T. J., Rhodes, C. S., & Pickett, T. C. (2024) · Military Medicine · doi:10.1093/milmed/usae334 · Cited by 2
Nightmare Disorder: An Overview
Robertson, B., Semenov, A., Skluzacek, T. J., Ly, H., & Miller, M. (2024) · Springer optimization and its applications · doi:10.1007/978-3-031-68263-6_11 · Cited by 2
Evidence-Based Prescribing of Prazosin in Post-Traumatic Stress Disorder
Kennedy, K. P. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00353-0 · Cited by 2
“…would suggest that benefit seen in clinical practice could reflect non-pharmacological factors rather than the specific pharmacological action of prazosin itself, as there is a robust placebo response in the major prazosin trials and in the treatment of sleep disturbances as a whole [3, 29, 30].”
InfluentialFarukh, B., Faconti, L., McNally, R., Moulton, C. D., Young, A. H., & Chowienczyk, P. (2025) · BJPsych Open · doi:10.1192/bjo.2025.64 · Cited by 2
“43,44 The atypical antipsychotic quetiapine is being increasingly used for depression, 45 has α 1 antagonist properties and reduces blood pressure, a feature shared by many other antipsychotics.”
Psychiatric Care of the Post-September 11 Combat Veteran: A Review
Johnson, J. M., & Capehart, B. P. (2018) · Psychosomatics · doi:10.1016/j.psym.2018.11.008 · Cited by 2
Khaw, C., & Argo, T. R. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.09.326 · Cited by 2
“It has been suggested that the collective body of evidence with prazosin in PTSD management maintains support of use in certain subsets of patients, and the PMPTC continues to be utilized in the VAHCS.24”
BackgroundInfluentialGaudette, E. V., Watling, S. E., Warsh, J. J., McCluskey, T., Tong, J., Houle, S., Rusjan, P., Rhind, S. G., Bazinet, R. P., Tyndale, R. F., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.729 · Cited by 2
Little, J. T., Llorente, B. A., & Llorente, M. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-05384-0_17 · Cited by 2
Treatment of Sleep Disorders in Specific Psychiatric Diseases
Wetter, T. C., & Steiger, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_451 · Cited by 2
Pharmacologic Treatment of Insomnia
Mishima, K. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_137 · Cited by 2
Мосолов, С. Н. (2022) · Современная терапия психических расстройств · doi:10.21265/psyph.2022.92.41.004 · Cited by 2
Toward a personalized medicine approach to trauma-related nightmares
Raskind, M. A. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101272 · Cited by 2
Self-citationBehandlung der PTBS bei Erwachsenen
Augsburger, M., Bering, R., Böttche, M., Ehring, T. W., Frommberger, U., Gast, U., Hecker, T., Hoffmann, A., Kleim, B., Knaevelsrud, C., et al. (2019) · Springer eBooks · doi:10.1007/978-3-662-59783-5_2 · Cited by 1
Pharmakotherapeutische Behandlung der Posttraumatischen Belastungsstörung
Schellong, J., Frommberger, U., Liebermann, P., Bering, R., & Schäfer, I. (2020) · Trauma und Gewalt · doi:10.21706/tg-14-2-102 · Cited by 2
The Role(s) of Psychopharmacology in the Treatment of PTSD
Baig, M. R., & Roache, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00150-x · Cited by 1
A wake-up call for “nightmares”
Mysliwiec, V., Brock, M. S., & Pruiksma, K. E. (2023) · SLEEP · doi:10.1093/sleep/zsad004 · Cited by 1
Naderi-far, N., Roohi, E., Sharifi, A., Jaafari, N., & Hashemian, F. (2024) · Drug Research · doi:10.1055/a-2226-3604 · Cited by 1
“No significant differences were found between drug and placebo groups in Clinician-Administered PTSD Scale, Pittsburgh Sleep Quality Index and Clinical Global Impression of Change scores following 10 weeks of treatment [40].”
BackgroundPetrakis, I. L., Nolen, T. L., Vandergrift, N., Hirsch, S. C., Krystal, J. H., Vivo, M. D., Sabados, J., Pisani, E., Newcomb, J., & Kosten, T. R. (2024) · American Journal on Addictions · doi:10.1111/ajad.13637 · Cited by 2
Psychopharmacology for Pediatric PTSD
Lauer-Arnold, I. J., Algon, S., & Hunt, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_15 · Cited by 3
Cheng, Q., Xu, S., Wang, J., Han, Y., Ge, Y., & Liu, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151061 · Cited by 3
Asimakopoulou, E., Theodosis‐Nobelos, P., & Triantis, C. (2024) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000139 · Cited by 2
Prazosin for the treatment of nightmares in hospitalized adult burn patients
Richardson, C. S., Hatch, E. S., Nakamura, Z. M., King, B. T., Williams, F. N., & Laughon, S. L. (2025) · Burns · doi:10.1016/j.burns.2025.107463 · Cited by 1
Roepke, S., Schoofs, N., Priebe, K., Wülfing, F., Roehle, R., Maslahati, T., Stieglbauer, K., Biedermann, S. V., Schaefer, I., Gallinat, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-098161 · Cited by 1
Richards, A. L., Santistevan, A. C., Yack, L. M., West, A. C., Berg, E., Pracar, S., Batki, S. L., Seal, K. H., & Neylan, T. C. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11908 · Cited by 1
“…a large multisite Veterans Affairs study demonstrated no benefit of prazosin over placebo for nightmares in a sample of 304 veterans with PTSD. 16 The latter results slightly dampened enthusi-asm for prazosin and underscored the critical need for research into alternative medications for this…”
InfluentialBest-Practice Mental Health Interventions Following Acute Cardiovascular Events
Abreu, M. N., Albuquerque, R. P., & Fonseca, A. (2026) · Cardiology Clinics · doi:10.1016/j.ccl.2025.12.005 · Cited by 2
Trauma-related nightmares: A Comprehensive and Integrative review
Feingold, D., Roseau, J.-B., Verdonk, C., Richards, A. L., Chennaoui, M., Saguin, E., & Léger, D. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102259 · Cited by 1
Ponomareva, O. Y., Stetson, S. R., Meltzer, B., Kim, K., & Kaplan, G. B. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002164 · Cited by 1
From Biomarkers to New Treatments for Post-Traumatic Stress Disorder
Wong, A. H. C., Wang, L., Shen, Y., & Liu, F. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01617-2 · Cited by 1
“The alpha-1 adrenergic receptor antagonist prazosin is widely used, but a large and well-designed clinical trial found it ineffective for reducing trauma-related nightmares or improving sleep quality in PTSD patients [9].”
Goldstein, D. S., & Eisenhofer, G. (2026) · Physiological Reviews · doi:10.1152/physrev.00005.2026 · Cited by 4
Felemban, R. G., Alzahrani, R. R., Alrefaei, N. F., Alharbi, N. M., Alghamdi, A. S., & Alqadi, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1857109 · Cited by 1
Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial
Roepke, S., Schoofs, N., Priebe, K., Wülfing, F., Meyer, K., Gieselmann, A., Stieglbauer, K., Gómez, M. G., Biedermann, S. V., Gallinat, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04546-9 · Cited by 2
“A detailed description of the outcome measures and the interrater reliability for primary outcome are provided in Supplementary Table 15.”
InfluentialTrauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders
Vojvoda, D., & Petrakis, I. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00013-4 · Cited by 1
The Case of Daniel Terzi: Trauma with Clinical Care
Fein, R., & Rosén, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-10952-3_5 · Cited by 1
Adrenoceptor Blockers: Influence on Depression and Anxiety
Cappetta, D., Urbanek, K., Berrino, L., & Angelis, A. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-90305-7_49-1 · Cited by 1
Psychiatric and Neurological Effects of Cardiovascular Drugs
Govoni, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-319-90305-7_46-1 · Cited by 1
Trauma and Posttraumatic Stress in Transitional-Age Youth
Kletter, H., Trager, E., Kang, J., Friedman, M., & Reicherter, D. (2021) · Springer eBooks · doi:10.1007/978-3-030-62113-1_8 · Cited by 2
van Schagen, A. M., & Lancee, J. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_8 · Cited by 1
Posttraumatische stressstoornis
van Schagen, A. M., & Vermetten, E. H. G. J. M. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_13 · Cited by 1
The treatment of post-traumatic nightmares requires more attention
Kim, E. S., & Kang, C. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-00988-0 · Cited by 1
“Systematic review and meta-analyses of RCTs in PTSD, including the PACT trial [8] (n = 589 [9], n = 429 [10]) Prazosin 3.”
MethodPTSD in Military Service Members and Veterans
Thompson‐Hollands, J., Lee, L. O., & Schnurr, P. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-18009-5_12 · Cited by 2
Prazosin for trauma-related nightmares in civilians at a Singapore hospital: a case series
Soh, K. C., & Tay, Y. H. (2024) · East Asian Archives of Psychiatry · doi:10.12809/eaap2344 · Cited by 1
Cardiac Autonomic Modulation in Domestic Cats with Obstructive Lower Urinary Tract Disease
Molina, M. M. T., Guimarães‐Okamoto, P. T. C., Aleixo, A. S. C., Tsunemi, M. H., Corrêa, J. V., de Melo, J. C., Machado, L. H. D. A., & Lourenço, M. L. G. (2024) · Animals · doi:10.3390/ani14233479 · Cited by 1
Scarpelli, S., Alfonsi, V., & Gennaro, L. D. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197602751.013.21 · Cited by 1
Neurobiology of post-traumatic stress disorder
Đorović, Đ., & Puškaš, L. (2025) · Medicinski podmladak · doi:10.5937/mp76-49506 · Cited by 1
Treatment of Sleep Disorders in Specific Psychiatric Diseases
Wetter, T. C., & Steiger, A. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_451-1 · Cited by 1
The Pharmacology of Parasomnias and Movement Disorders of Sleep
Carter, G. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100472 · Cited by 1
Adrenoceptor Blockers: Influence on Depression and Anxiety
Cappetta, D., Urbanek, K., Berrino, L., & Angelis, A. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-28008-6_49 · Cited by 1
McCall, W. V. (2020) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8296 · Cited by 1
Lancee, J., Yücel, D. E., Souama, C., & van Emmerik, A. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101286 · Cited by 1
Reappraising prazosin for night-time symptoms in post-traumatic stress disorder
Maguire, P. A., & Looi, J. C. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420910216 · Cited by 1
Ajibade, T. A. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7811 · Cited by 1
Therapeutic and adverse drug effects
Mollayeva, T., & Shapiro, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00023-2 · Cited by 1
Boukef, R., Youssef, R., Yaakoubi, H., Trabelsi, I., Sekma, A., Ali, K. B. H., Salah, H. B., Baccari, A., Boukadida, L., & Zorgati, A. (2022) · medRxiv · doi:10.1101/2022.01.12.22268879 · Cited by 1
“In recent years, the increasing of estimated prevalence of PTSD can be due partly to the improvement of the standardized evaluation procedure.[1]”
BackgroundManagement of posttraumatic stress disorder
Patel, B., & Youssef, N. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823039-8.00005-8 · Cited by 1
Thomas, C. L., Capaldi, V. F., & Collen, J. F. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11008 · Cited by 1
PTSD in midlife women: when deconstructing improves screening and influences care
Soares, C. N. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002446 · Cited by 1
Glymphatic function restored by α 1-noradrenergic antagonism alleviates headache allodynia in micePreprint
Pietra, A. D., Kuburas, A., Sevao, M., Castillo, T. M., Hanigan, Q. K., Duong, T. L., Flinn, H. C., Partridge, E. H., Raskind, M. A., Iliff, J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.720660 · Cited by 1
Self-citationPrazosin Is Ineffective for Chronic PTSD in Military Veterans
Roy‐Byrne, P. (2018) · Journal watch · doi:10.1056/nejm-jw.na46003
Aarre, T. F. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.18.0209
Vercillo, E., Santone, G., & Carnevali, R. (2019) · QUADERNI DI PSICOTERAPIA COGNITIVA · doi:10.3280/qpc2018-043002
Psychopharmakotherapie von Traumafolgestörungen
Bauer, M., Priebe, S., & Severus, E. (2019) · Springer eBooks · doi:10.1007/978-3-662-58470-5_19
Prevalencia y factores asociados a la depresión mayor en Andalucía
Porras‐Segovia, A. (2019) · Institutional Repository of the University of Granada (University of Granada) · Cited by 2
Noradrenergic Modulation of Stress-Induced Deficits in Fear Extinction
Giustino, T. F. (2019) · OakTrust (Texas A&M University Libraries)
Swift, K. A. (2019) · Deep Blue (University of Michigan)
An Integrated Mental Healthcare Model for the Patient with Sexual Trauma
Greene, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-38345-9_8
Updates on Pediatric Sleep Disorders
August, J., & Maski, K. P. (2020) · Current Sleep Medicine Reports · doi:10.1007/s40675-020-00184-w
Trauma- und belastungsbezogene Störungen
Wetter, T. C., Weber, F. C., & Klösch, G. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21321-2.00061-2
Acupuncture for Sleep Disturbances in Post-Deployment Military Service Members
(2019) · Case Medical Research · doi:10.31525/ct1-nct04031365
Zaitsev, D. V., Alekseieva, L. M., & Opanasenko, V. V. (2020) · Ukrainian Journal of Occupational Health · doi:10.33573/ujoh2020.04.311 · Cited by 1
Diokpa, C., Backe, K., & Pinsonnault, J. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2785
Prazosin for PTSD: Sorting out the evidence
Kendrick, J. (2021) · Current Psychiatry · doi:10.12788/cp.0117
Mäder, T. (2021) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-202200
Krystal, J. H., Chow, B. K., Vessicchio, J. C., Henrie, A. M., Neylan, T. C., Krystal, A. D., Marx, B. P., Xu, K., Jindal, R. D., Davis, L. L., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106540
Self-citationRusz, C.-M., Jîtcă, G., Miklos, A., Bătrînu, M.-G., Ősz, B. E., & Imre, S. (2021) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2021-0023
“Prazosin, an α1 adrenoreceptor antagonist, which initially showed promising results in treating sleep-related symptoms in PTSD, failed to demonstrate this effect in large randomized control trials [33, 34].”
ResultA Case Study of Prazosin-Induced Hypothermia
DiRocco, D., & Doddi, S. R. (2021) · American Journal of Psychiatry and Neuroscience · doi:10.11648/j.ajpn.20210903.17
“Several published studies support the usefulness of prazosin in PTSD for the management of associated nightmares but showed mixed results in randomized controlled trials [6-12].”
ResultReview of Select Sleep Medicine Pharmacology: Treatments of Hypersomnias and Parasomnia
Johnson, K., Mansukhani, M. P., & Kolla, B. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00163-8
Behavioral and Psychiatric Comorbidities of TBI
Collins, R. L., Combs, H. L., Miles, S. R., Pastorek, N. J., Tharp, A. T., & Kent, T. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-22436-3_14
Psychopharmacotherapy of Trauma Sequelae
Bauer, M., Priebe, S., & Severus, E. (2022) · Springer eBooks · doi:10.1007/978-3-662-64057-9_19
Psychiatric and Neurological Effects of Cardiovascular Drugs
Govoni, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-28008-6_46
Augustine, A. V. (2021) · Springer eBooks · doi:10.1007/978-3-030-65302-6_7
DiTommaso, C., Loughlin, S., & Falco, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-65385-5.00068-8
Metadata
- Authors
- Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D.
- Affiliations
- University of Washington (US)
- From the Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center (M.A.R., E.R.P., H.A.H., K.L.H., M.M.) and the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine (M.A.R., E.R.P., M.M.), Seattle; VA Cooperative Studies Program Coordinating Center, Palo Alto (B.C., M.-C.S., Y.L.), VA Long Beach Healthcare System, Department of Human Behavior, University of California, Irvine (C.R.), the Department of Health Research...
- Howard University (US)
- United States Department of Veterans Affairs (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 507-517
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2789959403
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 44 · 2023: 25 · 2022: 49 · 2021: 39 · 2020: 51 · 2019: 40 · 2018: 28
- FWCI
- 46.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- VA Cooperative Studies Program.
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- prazosin, post-traumatic stress disorder, military veterans, nightmares, chronic PTSD, alpha-blockers, sleep quality, blood pressure, adverse effects, PTSD pharmacotherapy, sleep disorders, sleep quality index, Clinician-Administered PTSD Scale, Clinical Global Impression of Change, dose escalation
- MeSH terms
- Adult, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Dreams, Female, Hospitals, Veterans, Humans, Male, Middle Aged, Prazosin, Psychiatric Status Rating Scales, Psychotherapy, Sleep, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, United States, Veterans, Treatment Failure, Adrenergic alpha-1 Receptor Antagonists, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.